Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials
A three-pronged acne treatment approach —combining an antibiotic, antibacterial agent, and retinoid—may provide greater efficacy than single/double treatments. Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide (BPO) 3.1% gel (IDP-126) is the first fixed-dose triple-combination in development for acne. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - September 1, 2023 Category: Dermatology Authors: Linda Stein Gold, Edward Lain, James Q. Del Rosso, Michael Gold, Zoe D. Draelos, Lawrence F. Eichenfield, Neil Sadick, William P. Werschler, Melinda J. Gooderham, Mary Lupo Tags: Original article Source Type: research
Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials
CONCLUSIONS: The results from these three studies show that the triple-combination IDP-126 had a positive safety profile and was well tolerated in healthy participants and those with moderate-to-severe acne.PMID:37341243 | DOI:10.1080/09546634.2023.2220446 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - June 21, 2023 Category: Dermatology Authors: Zoe D Draelos Emil A Tanghetti Leon H Kircik Neal Bhatia Joshua A Zeichner Jeffrey L Sugarman Linda Stein Gold Source Type: research
Clindamycin-benzoyl peroxide gel compared with clindamycin lotion for hidradenitis suppurativa; a randomized controlled assessor blinded intra-patient pilot study.
Background:
Antibiotic resistance is a major concern, especially in HS. However, antibiotics form a cornerstone in its treatment. Topical clindamycin is known to cause bacterial resistance, but is still advised as monotherapy for the treatment of mild to moderate HS
Methods
This is a randomized controlled, assessor blinded, intra-patient pilot trial to compare the clinical efficacy of clindamycin-benzoyl peroxide gel with clindamycin lotion in patients with mild to moderate HS. Two contralateral body sites were randomized for treatment in each patient. The primary outcome was the difference in the International Hidraden...
Source: Dermatology - April 20, 2023 Category: Dermatology Source Type: research
32970 Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized phase 2 and phase 3 studies of the first triple-combination drug
A 3-pronged approach to acne treatment —combining an antibiotic, antibacterial, and retinoid—may provide greater efficacy and tolerability than single/double treatments while potentially reducing antibiotic resistance and increasing patient compliance. Clindamycin 1.2%/BPO 3.1%/adapalene 0.15% (IDP-126) gel is the first triple-combin ation, fixed-dose topical acne product in development that addresses the major pathophysiological abnormalities in acne patients. A phase 2 (N = 741) and two phase 3 (N = 183; N = 180), double-blind, randomized, 12-week studies enrolled participants aged ≥9 years with moderate-to-severe ...
Source: Journal of the American Academy of Dermatology - September 1, 2022 Category: Dermatology Authors: Linda Stein Gold, Leon H. Kircik, Physicians Skin Care, PLLC, Emil A. Tanghetti Source Type: research
LB1031 Using social media to elucidate the patient experience with common acne treatments
Acne affects 50 million Americans annually and can have marked psychological effects on patients, who may also have poor experiences with different treatments. Our goal was to determine emotional sentiment associated with patient global impressions of change (PGIC) for common treatments. Through Brandwatch, a social media analysis tool, our team at The University of Illinois mined 90,121 social media posts pertaining to key words in relation to acne and expressions of satisfaction or disappointment, for twelve common treatments: adapalene, azelaic acid, benzoyl peroxide, clindamycin, dapsone, doxycycline, erythromycin, iso...
Source: Journal of Investigative Dermatology - July 20, 2022 Category: Dermatology Authors: B. Chandani, J. Jueng, R. Dellavalle, I. Brooks, O. Burton, S. Shaikh, V. Bhupalam, J. Solomon Source Type: research
Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients
CONCLUSIONS: CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.PMID:35833564 | DOI:10.1080/09546634.2022.2071823 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - July 14, 2022 Category: Dermatology Authors: Jonette Keri Fran E Cook-Bolden Lawrence Green Leon H Kircik Hilary Baldwin William Philip Werschler Eric Guenin Radhakrishnan Pillai Varsha Bhatt Source Type: research
A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris
CONCLUSIONS: Topical pharmacological treatment combinations, chemical peels and photochemical therapy were most effective for mild-to-moderate acne. Topical pharmacological treatment combinations, oral antibiotics combined with topical pharmacological treatments, oral isotretinoin, and photodynamic therapy were most effective for moderate-to-severe acne. Further research is warranted for chemical peels, photochemical and photodynamic therapies for which evidence was more limited.PMID:35789996 | DOI:10.1111/bjd.21739 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - July 5, 2022 Category: Dermatology Authors: Ifigneia Mavranezouli Caitlin H Daly Nicky J Welton Shalmali Deshpande Laura Berg Nathan Bromham Stephanie Arnold David M Phillippo Jane Wilcock Jingyuan Xu Jane C Ravenscroft Damian Wood Mohammed Rafiq Linyun Fou Katharina Dworzynski Eugene Healy Source Type: research
For Mild to Moderate Acne, Adapalene Plus Benzoyl Peroxide, Clindamycin Plus Benzoyl Peroxide, and Adapalene Alone Are Most Effective
Am Fam Physician. 2022 Jun 1;105(6):Online.NO ABSTRACTPMID:35704803 (Source: American Family Physician)
Source: American Family Physician - June 15, 2022 Category: Primary Care Authors: Mark H Ebell Source Type: research
For Mild to Moderate Acne, Adapalene Plus Benzoyl Peroxide, Clindamycin Plus Benzoyl Peroxide, and Adapalene Alone Are Most Effective
Am Fam Physician. 2022 Jun 1;105(6):Online.NO ABSTRACTPMID:35704803 (Source: American Family Physician)
Source: American Family Physician - June 15, 2022 Category: Primary Care Authors: Mark H Ebell Source Type: research
Clascoterone Cream (Winlevi) for Acne
Date: December 27, 2021
Issue #:
1640Summary:
The FDA has approvedWinlevi (Sun), a 1% cream
formulation of the androgen receptor inhibitor
clascoterone, for treatment of acne vulgaris in
patients ≥12 years old. It is the first topical androgen
receptor inhibitor to be approved by the FDA. (Source: The Medical Letter)
Source: The Medical Letter - December 10, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Acanya Acne Aczone Adapalene Aklief Altreno Amzeeq Antibacterials Arazlo Atralin Avita Azelaic acid Azelex Benzaclin Benzamycin Benzoyl peroxide Biacna clascoterone Cleocin Clindamycin Clindoxy Dalacin Dapsone Source Type: research
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
ConclusionsOnce-daily treatment with the novel fixed-dose triple-combination clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel demonstrated superior efficacy to vehicle and all three dyad component gels, and was well tolerated over 12 weeks in pediatric, adolescent, and adult participants with moderate-to-severe acne.Clinical Trial RegistrationClinicalTrials.gov identifier NCT03170388 (registered 31 May, 2017). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - October 21, 2021 Category: Dermatology Source Type: research
